Diag-Nose.io Clinches $2M Seed Funding to Revolutionize Respiratory Care
Deal News | Jan 30, 2025 | EIN
Diag-Nose.io has secured an oversubscribed $2 million seed funding round aimed at advancing AI applications in global respiratory care. The firm, which emerged from Stanford University's EENT Innovation Biodesign program, seeks to enhance the management of chronic respiratory diseases through its proprietary platform, RhinoMAP. Utilizing artificial intelligence and proteomics, RhinoMAP personalizes treatment plans, refining diagnostic processes and improving treatment outcomes. The company also offers the ABEL Microsampler, a nasal biopsy device that collects data for analysis via the AI-driven RhinoMAP system. Prominent investors including Breakthrough Victoria and Radar Ventures participated in this funding round, with Carl Stubbings joining the board as chairperson. Clinical trials in the U.S. are planned for 2025 to validate their innovations, which aim to transform respiratory care globally.
Sectors
- Biotechnology
- Healthcare
- Artificial Intelligence
- Venture Capital
Geography
- United States – Diag-Nose.io plans to conduct clinical trials in the U.S. in 2025 to validate its technology.
- Australia – The company is based in Melbourne, Australia, making it a significant geography in the article.
Industry
- Biotechnology – The article centers around Diag-Nose.io, a biotechnology company focused on advancing AI-driven precision medicine for respiratory care.
- Healthcare – The industry involved is healthcare, as the company aims to improve the management and treatment of chronic respiratory diseases.
- Artificial Intelligence – AI is crucial in the development of Diag-Nose.io's RhinoMAP platform for personalizing respiratory disease treatments.
- Venture Capital – The article discusses a seed funding round, a key activity in venture capital investment.
Financials
- $2M – Seed funding round raised by Diag-Nose.io for advancing AI in respiratory care.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Diag-Nose.io | Target Company | Company | Diag-Nose.io is a biotechnology company focused on AI-driven diagnostics for respiratory diseases. |
| Breakthrough Victoria | Investor | Company | One of the investors in Diag-Nose.io's seed funding round. |
| Radar Ventures | Investor | Company | Participated in Diag-Nose.io's seed funding round. |
| Specialty Physician Associates | Investor | Company | Another investor in the seed round for Diag-Nose.io. |
| Carl Stubbings | Board Chairperson | Person | Newly appointed chairperson of Diag-Nose.io's board. |
| Eldin Rostom | CEO and Co-Founder | Person | CEO and Co-Founder of Diag-Nose.io. |